RGEN Repligen Corporation

Repligen Corporation to Present at Upcoming May Investor Conferences

Repligen Corporation to Present at Upcoming May Investor Conferences

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.

  • RBC Capital Markets’ 2024 Global Healthcare Conference, being held in New York on May 14-15. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 14, 2024 at 10:30 a.m. ET, in addition to a series of one-on-one meetings with investors.
  • Craig-Hallum’s 21st Annual Institutional Investor Conference, being held in Minneapolis on May 29. Jason K. Garland, Chief Financial officer will participate in a series of one-on-one meetings with investors.
  • Leerink Partners’ 2024 Healthcare Crossroads Conference, being held in Austin, Texas on May 28-29. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 30, 2024 at 8:40 a.m. CT, in addition to a series of one-on-one meetings with investors.

A live webcast of the RBC and Leerink conference presentations will be accessible through Repligen’s  website at , and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at , and follow us on .

Repligen Contact:

Sondra S. Newman

Global Head of Investor Relations

(781) 419-1881



EN
07/05/2024

Underlying

RGENRepligen Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Repligen Corporation

 PRESS RELEASE
Free
RGEN Repligen Corpor...

Repligen Corporation to Present at Upcoming May Investor Conferences

Repligen Corporation to Present at Upcoming May Investor Conferences WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC Capital Markets’ 2024 Global Healthcare Conference, being held in New York on May 14-15. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 14, 2024 at 10:30 a.m. ET, in addition to a series of one-on-one meetings wit...

May 7, 2024 1 EN
 PRESS RELEASE
Free
RGEN Repligen Corpor...

Repligen Reports First Quarter 2024 Financial Results

Repligen Reports First Quarter 2024 Financial Results Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-yearIncreased Filtration (non-COVID) revenue by 12% year-over-yearAchieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The company also reiterated its financial guidan...

May 1, 2024 1 EN
 PRESS RELEASE
Free
RGEN Repligen Corpor...

Repligen to Report First Quarter 2024 Financial Results

Repligen to Report First Quarter 2024 Financial Results Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2024 financial results on Wednesday, May 1, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2024. The conference call will be acces...

April 17, 2024 1 EN
 PRESS RELEASE
Free
RGEN Repligen Corpor...

Repligen Appoints Maggie A. Pax to Board of Directors

Repligen Appoints Maggie A. Pax to Board of Directors WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen’s board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she served as Vice President, Strategy and Innov...

March 19, 2024 1 EN
Free Trial
RGEN Repligen Corpor...

Repligen Corp: 1 director

A director at Repligen Corp sold 16,706 shares at 197.440USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

RGEN REPLIGEN CORPORATION
03/12/24 March 12, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch